A Phase 3, Randomized, Double-Blind Study of COSELA or Placebo in Patients Receiving First- or Second-Line Gemcitabine and Carboplatin Chemotherapy for Locally Advanced Unresectable or Metastatic Triple-Negative Breast Cancer (PRESERVE-2)
Research payments
$10,805,321
Through program year 2022, $10,805,321 in research payments was reported against A Phase 3, Randomized, Double-Blind Study of COSELA or Placebo in Patients Receiving First- or Second-Line Gemcitabine and Carboplatin Chemotherapy for Locally Advanced Unresectable or Metastatic Triple-Negative Breast Cancer (PRESERVE-2), across 2,033 payments, paid by G1 Therapeutics, Inc..
- Paid by
- G1 Therapeutics, Inc.
- ClinicalTrials.gov
- No trial number was reported for this study
By program year
1 row| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2022 | Research | $10,805,321 | 2,033 |
Breakdown
Usually the institution or organisation running the study, not a person.
Records
Every payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
Principal investigators named
10 shownNamed on the study's payments. Being named is not being paid: the money in the figures above went to the recipients listed, not necessarily to these people.
- David Berz Beverly Hills, CA Named on 138 payments
- Meredith McKean Houston, TX Named on 99 payments
- Elizabeth Guancial Rochester, NY Named on 78 payments
- Manojkumar Bupathi Athens, OH Named on 74 payments
- Danko Martincic Greenacres, WA Named on 64 payments
- Santosh Nair Deland, FL Named on 54 payments
- Afshin Gabayan Beverly Hills, CA Named on 50 payments
- Rahul Ravilla Albany, NY Named on 46 payments
- Sara Hurvitz Los Angeles, CA Named on 46 payments
- Ian Schnadig Portland, OR Named on 43 payments
What you are looking at
Research payments are tied to a study. Being named on a study as a principal investigator is reported separately from being paid as a recipient, and the two are not the same thing — a named investigator has not necessarily received the money.